The G-BA has received an application for a § 137h SGB V consultation for endoscopic duodenal thermoablation in type 2 diabetes
Hospitals applying for first-time innovation funding (NUB) for a high-risk medical (class IIb, III or active implants) devices in Germany have to undergo an elaborate evaluation procedure by the Federal Joint Committee (G-BA). The G-BA announced that a consultation regarding the eligibility of a § 137h evaluation of endoscopic duodenal thermoablation in type 2 diabetes was requested.
The main criterion will be the novelty of the theoretical-scientific concept of the method. Hospitals intending to use the method and affected medical device manufacturers have the opportunity to hand in additional material on the method until June 29th 2017. A verbal hearing is planned for June 13th 2017. Submission of documents and the initial application form can be found on the G-BA’s website.